Zhu Hong, Ning Yanzhe, Zheng Sisi, Feng Sitong, Dong Linrui, Jia Hongxiao
Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
Front Psychiatry. 2023 Jun 27;14:1160452. doi: 10.3389/fpsyt.2023.1160452. eCollection 2023.
To date, there is no conclusive evidence for early interventions on ultra-high risk (UHR) for psychosis. The Chinese herbal medicine is confirmed to be beneficial in improving psychiatric symptoms and cognitive impairments for schizophrenia patients. However, the effect of Chinese herbal medicine on treating UHR patients remains unknown.
Eighty UHR patients were recruited from the outpatient department. They were randomly assigned to receive either Shi-Zhen-An-Shen herbal formula granule (SZAS-HFG) combined with aripiprazole placebo or aripiprazole combined with SZAS-HFG placebo for a 12-week treatment. The psychiatric symptoms were assessed using the Structured Interview for Prodromal Syndromes (SIPS). The Trail Making Test part A (TMT-A), Brief Visuospatial Memory Test (BVMT), Hopkins Verbal Learning Test (HVLT), and Continuous Performance Test (CPT) were used to assess cognitive functions. we also employed the Global Assessment of Functioning (GAF) to evaluate social functioning. The linear mixed-effects models were performed to detect the difference in effectiveness between the two groups.
After 12-week treatment, both groups showed significant effects of time on SIPS, TMT-A, HVLT, BVMT, and GAF. There was a significant effect of group only on CPT. Moreover, we also found a significant interaction effect on GAF.
SZAS-HFG can effectively alleviate psychosis symptoms, and improve cognitive impairments and overall functioning as well as aripiprazole. Chinese Clinical Trial Registry, ChiCTR-IOR-17013513.
迄今为止，尚无确凿证据支持对超高危精神病风险（UHR）进行早期干预。已证实中药对改善精神分裂症患者的精神症状和认知障碍有益。然而，中药对治疗UHR患者的效果仍不清楚。
从门诊招募了80名UHR患者。他们被随机分配接受石贞安神中药配方颗粒（SZAS-HFG）联合阿立哌唑安慰剂或阿立哌唑联合SZAS-HFG安慰剂，进行为期12周的治疗。使用前驱综合征结构化访谈（SIPS）评估精神症状。使用连线测验A部分（TMT-A）、简短视觉空间记忆测验（BVMT）、霍普金斯言语学习测验（HVLT）和持续操作测验（CPT）评估认知功能。我们还采用功能总体评定量表（GAF）评估社会功能。采用线性混合效应模型检测两组疗效差异。
经过12周的治疗，两组在SIPS、TMT-A、HVLT、BVMT和GAF上均显示出时间的显著影响。仅在CPT上存在组间显著影响。此外，我们还发现了GAF上的显著交互作用。
SZAS-HFG能有效缓解精神病症状，改善认知障碍和整体功能，与阿立哌唑效果相当。中国临床试验注册中心，ChiCTR-IOR-17013513。
